Nanocarrier-Based Drug Delivery Systems for Lung Cancer: A Systematic Review and Meta-Analysis of Preclinical Studies
Advances in Respiratory Medicine · 24.07.2026 · 94 (4) · 50
DOI: 10.3390/arm94040050 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Advances in Respiratory Medicine, online erschienen am 24.07.2026. Verfasst von Pranvera Breznica Selmani und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical Chemistry, Pharmacy Division, Faculty of Medicine, University of Prishtina, 10000 Prishtina, Kosovo. Hauptthemen laut MEDLINE: Lung Neoplasms, Antineoplastic Agents, Drug Delivery Systems, Nanoparticles. Die Arbeit nennt 59 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Drug delivery systems (DDS) may improve the therapeutic performance of chemotherapy in lung cancer, but their preclinical efficacy has not been quantitatively synthesized. We conducted a systematic review and meta-analysis of controlled in vivo mouse studies evaluating DDS-based chemotherapeutic formulations for lung cancer. Databases were searched from inception to 15 February 2025, and methodological quality was assessed using the SYRCLE risk-of-bias tool. Thirty studies comprising 47 experiments were included. Compared with corresponding free-drug treatments, DDS-based chemotherapy significantly reduced tumor volume (WMD −310.67 mm3; 95% CI: −375.51 to −245.83; p < 0.001), although substantial heterogeneity was observed. Both targeted and non-targeted DDS were associated with tumor growth inhibition, and targeted formulations showed a larger average reduction; however, this finding should be interpreted in light of differences in formulation properties, tumor models, and treatment protocols. Nanoparticle, liposomal, and micellar platforms all demonstrated significant antitumor effects, while combination DDS and docetaxel- or cisplatin-based systems showed large effects in subgroup analyses with variable sample sizes. These findings support the continued development of DDS-based chemotherapy for lung cancer, but standardized reporting of nanocarrier characterization, pharmacokinetics, biodistribution, toxicity, and rigorous animal-study design is required to improve reproducibility and translational relevance.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmaceutical Chemistry, Pharmacy Division, Faculty of Medicine, University of Prishtina, 10000 Prishtina, Kosovo.
- Department of Clinical Pharmacy and Biopharmacy, Pharmacy Division, Faculty of Medicine, University of Prishtina, 10000 Prishtina, Kosovo.
- Department of Pharmaceutical Technology, Pharmacy Division, Faculty of Medicine, University of Prishtina, 10000 Prishtina, Kosovo.
- Department of Dentistry, Faculty of Medicine, University of Prishtina, 10000 Prishtina, Kosovo.
ORCID-Profile: Pranvera Breznica Selmani, Zana Sllamniku Dalipi, Rozafa Koliqi
Zitieren
APA
Breznica Selmani, P., Grapci, A. D., Koshi, B., Sllamniku Dalipi, Z., & Koliqi, R. (2026). Nanocarrier-Based Drug Delivery Systems for Lung Cancer: A Systematic Review and Meta-Analysis of Preclinical Studies. Advances in Respiratory Medicine, 94(4), 50. https://doi.org/10.3390/arm94040050
Vancouver
Breznica Selmani P, Grapci AD, Koshi B, Sllamniku Dalipi Z, Koliqi R. Nanocarrier-Based Drug Delivery Systems for Lung Cancer: A Systematic Review and Meta-Analysis of Preclinical Studies. Advances in Respiratory Medicine. 2026;94(4):50. doi:10.3390/arm94040050
BibTeX
@article{BreznicaSelmani2026,
author = {Breznica Selmani, Pranvera and Grapci, Arlinda Daka and Koshi, Blerina and Sllamniku Dalipi, Zana and Koliqi, Rozafa},
title = {Nanocarrier-Based Drug Delivery Systems for Lung Cancer: A Systematic Review and Meta-Analysis of Preclinical Studies},
journal = {Advances in Respiratory Medicine},
year = {2026},
volume = {94},
number = {4},
pages = {50},
doi = {10.3390/arm94040050}
}
EUVIMED